Combination Enzalutamide and Radium-223 Extends Overall Survival in Bone-Dominant mCRPC - Summary - MDSpire
Clinical Guidelines

Combination Enzalutamide and Radium-223 Extends Overall Survival in Bone-Dominant mCRPC

In the final analysis of the phase III EORTC 1333/PEACE-3 trial, with a median follow-up of 58 months, the addition of radium-223 to the androgen receptor inhibitor enzalutamide significantly prolonge...

  • By

  • Caroline Helwick

  • May 14, 2026

  • 8 min

Share

The phase III EORTC 1333/PEACE-3 trial revealed that combining radium-223 with enzalutamide significantly improved overall survival in patients with bone-dominant metastatic castration-resistant prostate cancer (mCRPC), as reported at the 2026 ASCO Genitourinary Cancers Symposium. The treatment resulted in a 24% reduction in prostate cancer mortality and extended overall survival by nearly 6 months compared to enzalutamide alone. Involving 446 patients, the study demonstrated crucial findings in survival benefits and toxicity profiles, emphasizing the need for careful integration into treatment regimens.

Original Source(s)

Combination Enzalutamide and Radium-223 Extends Overall Survival in Bone-Dominant mCRPC

  • by Caroline Helwick

  • May 14, 2026

Related Content

Does the Timing of Immunotherapy Administration Affect Outcomes in Advanced Cancers?

A systematic review and meta-analysis found that early time-of-day immunotherapy was associated with improved survival outcomes in patients with advanced cancers, with the association appearing to be ...

Lack of Research in Understanding the Global Population of Childhood Cancer Survivors Leads to Gaps in Care and Cures

Each year, globally, about 400,000 children and adolescents aged between 0 and 19 years are diagnosed with cancer; over 100,000 die from the disease, with most of those cases, over 80%, and deaths occ...

New Clues in Hodgkin Lymphoma Biology

Transcriptome analysis highlights diagnostic targets and immune evasion pathways

  • May 14, 2026

  • 2 min